Previous 10 | Next 10 |
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the submission of a Marketing Authorization Application to t...
Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Andrei Shustov, M.D., Professor of Medicine and Hemat...
Verastem, Inc. (NASDAQ: VSTM) (the “Company”) today announced that it has entered into privately negotiated agreements among the Company and a limited number of investors who are accredited investors (within the meaning of Rule 501 promulgated under the Securities Act of 1933, a...
Results from the Dose Optimization Portion of the Study to be Presented PRIMO Expansion Phase To Investigate Duvelisib 75mg Twice Daily for Two Cycles, Followed by 25mg Twice Daily Four Additional Abstracts Selected for Presentation, Including Results from a Phase 1 Study Investi...
Verastem Oncology ( VSTM ) reported their Q3 earnings with a notable beat on EPS and revenue. Verastem's flagship product, COPIKTRA, just completed its fourth full quarter pulling about $4M sales , which is a 33% increase over Q2. This puts the company on track to accomplish their $12M to $...
Verastem, Inc. (VSTM) Q3 2019 Earnings Conference Call October 29, 2019 4:30 PM ET Company Participants John Doyle - Vice President of Investor Relations & Finance Brian Stuglik - Chief Executive Officer Dan Paterson - President & Chief Operating Officer Rob Gagnon - Ch...
Verastem (NASDAQ: VSTM ): Q3 Non-GAAP EPS of -$0.35 beats by $0.08 ; GAAP EPS of -$0.41 beats by $0.02 . Revenue of $9M (-42.0% Y/Y) beats by $1.48M . Shares +4.8% . Press Release More news on: Verastem, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks ...
Company Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance Cash, Cash Equivalents and Short-Term Investments of $160.2 Million as of September 30, 2019 Company to Streamline Organization and Red...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that five posters highlighting clinical data for COPIKTRA...
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that the Company will host a conference call and webcast on ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...